Glaxo Flovent metered dose inhaler NDA should adhere to FDA guidance on reformulations -- Forest petition.
GLAXO FLOVENT FORMULA SHOULD MEET STANDARDS IN FDA MDI GUIDANCE, FOREST Labs asserts in a Nov. 17 citizen petition to the agency. The petition, submitted on behalf of Forest Labs by the D.C. law firm of Kleinfeld, Kaplan & Becker, requests that FDA not approve Glaxo Wellcome's metered-dose inhaler product Flovent (fluticasone propionate) until the company conducts the types of studies laid out in FDA's 1994 "Points to Consider" document on development of MDI products ("The Pink Sheet" July 18, 1994, T&G-4).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth